1. Home
  2. CMS vs INSM Comparison

CMS vs INSM Comparison

Compare CMS & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CMS Energy Corporation

CMS

CMS Energy Corporation

HOLD

Current Price

$67.52

Market Cap

21.5B

Sector

Utilities

ML Signal

HOLD

Logo Insmed Incorporated

INSM

Insmed Incorporated

HOLD

Current Price

$95.56

Market Cap

22.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CMS
INSM
Founded
1987
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Power Generation
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.5B
22.4B
IPO Year
1997
2000

Fundamental Metrics

Financial Performance
Metric
CMS
INSM
Price
$67.52
$95.56
Analyst Decision
Buy
Strong Buy
Analyst Count
15
24
Target Price
$75.83
★ $197.00
AVG Volume (30 Days)
★ 3.9M
2.6M
Earning Date
10-27-2026
10-29-2026
Dividend Yield
★ 3.32%
N/A
EPS Growth
★ 6.01
N/A
EPS
★ 1.47
N/A
Revenue
★ $8,539,000,000.00
N/A
Revenue This Year
$4.97
$196.85
Revenue Next Year
$4.71
$61.71
P/E Ratio
$46.90
★ N/A
Revenue Growth
★ 13.63
N/A
52 Week Low
$62.29
$90.39
52 Week High
$80.36
$212.75

Technical Indicators

Market Signals
Indicator
CMS
INSM
Relative Strength Index (RSI) 59.31 29.46
Support Level $67.19 $90.39
Resistance Level $69.36 $119.54
Average True Range (ATR) 1.08 3.84
MACD 0.63 -0.82
Stochastic Oscillator 77.64 8.96

Price Performance

Historical Comparison
CMS
INSM

About CMS CMS Energy Corporation

CMS Energy is an energy holding company with three principal businesses. Its regulated utility, Consumers Energy, provides regulated natural gas service to 1.8 million customers and electric service to 1.9 million customers in Michigan. NorthStar Clean Energy, formerly CMS Enterprises, is engaged in wholesale power generation, including contracted renewable energy. CMS sold EnerBank in October 2021.

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.

Share on Social Networks: